ClinConnect ClinConnect Logo
Search / Trial NCT04356105

Protocols of IVF/ICSI in Poor Responders

Launched by CAIRO UNIVERSITY · Apr 18, 2020

Trial Information

Current as of June 04, 2025

Completed

Keywords

ClinConnect Summary

The two groups of poor responders are randomized into either; a minimal dose stimulation protocol involving letrozole, recombinant FSH and GnRH antagonist versus a microflare conventional protocol with OCP, GnRH agonist and high dose recombinant FSH, in their IVF/ICSI cycles, primary outcome will be the number of oocytes retrieved.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1- More than 1 year of infertility 2 - Poor ovarian responder according to the Bologna criteria:
  • 1. Advanced maternal age
  • 2. Previous poor ovarian response
  • 3. Abnormal tests of ovarian reserve (AFC \< 5-7, AMH \<0.5-1.1 ng/ml)
  • Exclusion Criteria:
  • 1. Age \> 43 years
  • 2. baseline FSH \>15 mIU/ml
  • 3. Previous ovarian surgery
  • 4. Ovarian endometrioma
  • 5. Uterine anomaly or myoma
  • 6. Any medical disorder
  • 7. Any hormonal disorder eg. hyperprolactinemia
  • 8. BMI \> 30 kg/m2
  • 9. Severe male factor

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Cairo, , Egypt

Cairo, , Egypt

Patients applied

0 patients applied

Trial Officials

Sarwat Ahwany, MD

Study Director

Cairo University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials